Compare DTCX & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DTCX | RFL |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Real Estate |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.3M | 92.6M |
| IPO Year | 2021 | 2017 |
| Metric | DTCX | RFL |
|---|---|---|
| Price | $1.98 | $1.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 74.9K | ★ 92.2K |
| Earning Date | 04-13-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.00 | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | $2,446.00 | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $1.51 | $1.12 |
| 52 Week High | $3.80 | $3.96 |
| Indicator | DTCX | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 53.39 | 40.50 |
| Support Level | $1.83 | $1.21 |
| Resistance Level | $2.06 | $2.16 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 71.88 | 17.95 |
Datacentrex Inc is a digital infrastructure and capital deployment company that owns and operates Scrypt compute assets and evaluates strategic transactions across asset-backed operating businesses. Its current operating platform is centered on owned and operated Scrypt-based proof-of-work compute deployed through third-party colocation facilities. Datacentrex monetizes this compute through hashrate marketplace mechanisms and manages a treasury of digital assets and cash in a manner intended to preserve capital and support opportunistic, accretive deployment. The company's operations are principally operated remotely at various data centers throughout the United States.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.